Effects of Changes in Number of Medications and Drug Burden Index Exposure on Transitions between Frailty States and Death: The Concord Health and Ageing in Men Project Cohort Study

Journal of the American Geriatrics Society

Volumn 64, Issue 1, 2016, Pages 89-95

  Jamsen, Kris M ^a,b   Bell, J Simon ^a,b,c   Hilmer, Sarah N ^b,d   Kirkpatrick, Carl M J ^a   Ilomäki, Jenni ^a   Le Couteur, David ^e,f,g   Blyth, Fiona M ^e,f   Handelsman, David J ^e,g   Waite, Louise ^g   Naganathan, Vasi ^e,f   Cumming, Robert G ^f,h   Gnjidic, Danijela ^f,i  

^a MONASH UNIVERSITY   (Australia)

^b HORNSBY KU RING GAI HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Centre for Education and Research on Ageing   (Australia)

^g ANZAC Research Institute   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

Author keywords

epidemiological methods; frail elderly; medication; mortality

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; SEDATIVE AGENT; PRESCRIPTION DRUG;

AGED; ARTICLE; AUSTRALIA; CORRELATIONAL STUDY; DEATH; DRUG BURDEN INDEX; FRAILTY; FUNCTIONAL DISEASE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; RISK ASSESSMENT; VERY ELDERLY; AGING; CLINICAL TRIAL; DEMENTIA; FOLLOW UP; FRAIL ELDERLY; HEALTH STATUS; MORBIDITY; MULTICENTER STUDY; NEW SOUTH WALES; QUESTIONNAIRE; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; TRENDS;

AGED; AGED, 80 AND OVER; AGING; DEMENTIA; FOLLOW-UP STUDIES; FRAIL ELDERLY; HEALTH STATUS; HUMANS; MALE; MORBIDITY; NEW SOUTH WALES; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES;

EID: 84961338709     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13877     Document Type: Article

References (37)

1. Maher RL, Hanlon J, Hajjar ER,. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014; 13: 57-65.
2. Jyrkka J, Enlund H, Korhonen MJ, et al., Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: Results of the Kuopio 75 + study: A cross-sectional analysis. Drugs Aging 2009; 26: 493-503.
3. Hajjar ER, Cafiero AC, Hanlon JT,. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5: 345-351.
4. Pitkala KH, Juola AL, Kautiainen H, et al., Education to reduce potentially harmful medication use among residents of assisted living facilities: A randomized controlled trial. J Am Med Dir Assoc 2014; 15: 892-898.
5. Hilmer SN, Mager DE, Simonsick EM, et al., Drug burden index score and functional decline in older people. Am J Med 2009; 122: 1142-1149.
6. Gnjidic D, Hilmer SN, Hartikainen S, et al., Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer's disease: A national population cohort study. PLoS ONE 2014; 9: e83224.
7. Nishtala PS, Narayan SW, Wang T, et al., Associations of drug burden index with falls, general practitioner visits, and mortality in older people. Pharmacoepidemiol Drug Saf 2014; 23: 753-758.
8. Fried LP, Tangen CM, Walston J, et al., Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56A: M146-M156.
9. Hoogendijk EO, van Hout HP, Heymans MW, et al., Explaining the association between educational level and frailty in older adults: Results from a 13-year longitudinal study in the Netherlands. Ann Epidemiol 2014; 24: 538.e532-544.e532.
10. Lee JS, Auyeung TW, Leung J, et al., Transitions in frailty states among community-living older adults and their associated factors. J Am Med Dir Assoc 2014; 15: 281-286.
11. Gnjidic D, Hilmer SN, Blyth FM, et al., High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther 2012; 91: 521-528.
12. Boyd CM, Xue QL, Simpson CF, et al., Frailty, hospitalization, and progression of disability in a cohort of disabled older women. Am J Med 2005; 118: 1225-1231.
13. Yun H, Delzell E, Ensrud KE, et al., Predicting hip and major osteoporotic fractures using administrative data. Arch Intern Med 2010; 170: 1940-1942.
14. Woods NF, LaCroix AZ, Gray SL, et al., Frailty: Emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc 2005; 53: 1321-1330.
15. Clegg A, Young J, Iliffe S, et al., Frailty in elderly people. Lancet 2013; 381: 752-762.
16. Crentsil V, Ricks MO, Xue QL, et al., A pharmacoepidemiologic study of community-dwelling, disabled older women: Factors associated with medication use. Am J Geriatr Pharmacother 2010; 8: 215-224.
17. Gill TM, Gahbauer EA, Allore HG, et al., Transitions between frailty states among community-living older persons. Arch Intern Med 2006; 166: 418-423.
18. Gnjidic D, Johnell K,. Clinical implications from drug-drug and drug-disease interactions in older people. Clin Exp Pharmacol Physiol 2013; 40: 320-325.
19. Cumming RG, Handelsman D, Seibel MJ, et al., Cohort profile: The Concord Health and Ageing in Men Project (CHAMP). Int J Epidemiol 2009; 38: 374-378.
20. Hilmer SN, Mager DE, Simonsick EM, et al., A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167: 781-787.
21. Donohoo E,. MIMS Annual 2007. Sydney, Australia: CMPMedica Australia, 2007.
22. Fried LP, Ferrucci L, Darer J, et al., Untangling the concepts of disability, frailty, and comorbidity: Implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004; 59A: 255-263.
23. Blyth FM, Rochat S, Cumming RG, et al., Pain, frailty and comorbidity on older men: The CHAMP study. Pain 2008; 140: 224-230.
24. Gnjidic D, Le Couteur DG, Hilmer SN, et al., Sedative load and functional outcomes in community-dwelling older Australian men: The CHAMP study. Fundam Clin Pharmacol 2012; 28: 10-19.
25. Groll DL, To T, Bombardier C, et al., The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol 2005; 58: 595-602.
26. Kay R,. A Markov Model for analysing cancer markers and disease states in survival studies. Biometrics 1986; 42: 855-865.
27. Kalbeisch J, Lawless J,. The analysis of panel data under a Markov assumption. J Am Statist Assoc 1985; 80: 863-871.
28. Cox DR, Miller HD,. The Theory of Stochastic Processes. London: Chapman and Hall, 1965.
29. Kulmala J, Nykanen I, Hartikainen S,. Frailty as a predictor of all-cause mortality in older men and women. Geriatr Gerontol Int 2014; 14: 899-905.
30. Jackson CH,. Multi-state models for panel data: The msm package for R. J Statistical Software 2011; 38: 1-29.
31. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2013.
32. Sterne JA, Davey Smith G,. Sifting the evidence-what's wrong with significance tests? BMJ 2001; 322: 226-231.
33. Morley JE, Vellas B, van Kan GA, et al., Frailty consensus: A call to action. J Am Med Dir Assoc 2013; 14: 392-397.
34. Lau HS, de Boer A, Beuning KS, et al., Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997; 50: 619-625.
35. Holden CA, McLachlan RI, Pitts M, et al., Men in Australia Telephone Survey (MATeS): A national survey of the reproductive health and concerns of middle-aged and older Australian men. Lancet 2005; 366: 218-224.
36. Lee KJ, Carlin JB,. Recovery of information from multiple imputation: A simulation study. Emerg Themes Epidemiol 2012; 9: 3.
37. Karahalios A, Baglietto L, Lee KJ, et al., The impact of missing data on analyses of a time-dependent exposure in a longitudinal cohort: A simulation study. Emerg Themes Epidemiol 2013; 10: 6.